Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-10

Study Completion Date

2015-02-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, beginning most often in subjects aged 20-40 years. In France, thanks to recent studies reported during general states of MS in 2006, the prevalence is estimated at 65.5 / 100,000 population (96.3 / 100,000 women and 41.9 / 100,000 men) and incidence at 7.91 per 100,000. In Lower Normandy, the incidence of MS is estimated to 4.45 / 100,000 inhabitants or 60 new cases per year.

The primary objective of this pilot study is to assess the levels of glutamate and aspartate (excitotoxicity markers) and their repercussions on the clinical and radiological outcome in 40 patients experiencing an event demyelinating central nervous system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis

NCT03632473

Multiple Sclerosis

COMPLETED

Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics

NCT03854123

Multiple Sclerosis

COMPLETED

Plasma Exchanges in Multiple Sclerosis (MS) Relapses

NCT01442233

Multiple Sclerosis Multiple Sclerosis, Acute Relapsing

COMPLETED PHASE3

Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis

NCT00997438

Multiple Sclerosis

COMPLETED PHASE1

Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases

NCT05088473

Central Nervous System Diseases Multiple Sclerosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Volunteers

Group Type OTHER

glutamate and aspartate

Intervention Type BIOLOGICAL

Multiple Sclerosis patient

Group Type OTHER

glutamate and aspartate

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

glutamate and aspartate

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman between 18 and 60 years old.
* Patient with one or more type of inflammatory events of Central system suggestive of demyelinating disease (multiple sclerosis, neuromyelitis optical Devic extensive myelitis)
* No treatment with corticosteroids for less than 1 month
* Need for a lumbar puncture performed in the etiologic
* Need a brain MRI performed within the etiologic
* Patient who signed informed consent

Exclusion Criteria

* Secondary progressive MS
* Any cons-indication for lumbar puncture
* Any contra-indication to MRI
* Minor patient or patient major under guardianship

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes